<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23726161</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>381</Volume><Issue>9882</Issue><PubDate><Year>2013</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</ArticleTitle><Pagination><StartPage>2024</StartPage><EndPage>2032</EndPage><MedlinePgn>2024-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(13)61049-1</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(13)61049-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A vaccine for enterovirus 71 (EV71) is needed to address the high burden of disease associated with infection. We assessed the efficacy, safety, immunogenicity, antibody persistence, and immunological correlates of an inactivated alum-adjuvant EV71 vaccine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We did a randomised, double-blind, placebo-controlled, phase 3 trial. Healthy children aged 6-35 months from four centres in China were randomly assigned (1:1) to receive vaccine or alum-adjuvant placebo at day 0 and 28, according to a randomisation list (block size 30) generated by an independent statistician. Investigators and participants and their guardians were masked to the assignment. Primary endpoints were EV71-associated hand, foot, and mouth disease (HFMD) and EV71-associated disease during the surveillance period from day 56 to month 14, analysed in the per-protocol population. This study is registered with ClinicalTrials.gov, number NCT01508247.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">10,245 participants were enrolled and assigned: 5120 to vaccine versus 5125 to placebo. 4907 (with three cases of EV71-associated HFMD and eight cases of EV71-associated disease) versus 4939 (with 30 cases of EV71-associated HFMD and 41 cases of EV71-associated disease) were included in the primary efficacy analysis. Vaccine efficacy was 90&#xb7;0% (95% CI 67&#xb7;1-96&#xb7;9) against EV71-associated HFMD (p=0&#xb7;0001) and 80&#xb7;4% (95% CI 58&#xb7;2-90&#xb7;8) against EV71-associated disease (p&lt;0&#xb7;0001). Serious adverse events were reported by 62 of 5117 (1&#xb7;2%) participants in the vaccine group versus 75 of 5123 (1&#xb7;5%) in the placebo group (p=0&#xb7;27). Adverse events occurred in 3644 (71&#xb7;2%) versus 3603 (70&#xb7;3%; p=0&#xb7;33).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">EV71 vaccine provides high efficacy, satisfactory safety, and sustained immunogenicity.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">China's 12-5 National Major Infectious Disease Program, Beijing Vigoo Biological.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Feng-Cai</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China. jszfc@vip.sina.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fan-Yue</ForeName><Initials>FY</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing-Xin</ForeName><Initials>JX</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiu-Ling</ForeName><Initials>XL</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qun-Ying</ForeName><Initials>QY</Initials></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-Tao</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qing-Hua</ForeName><Initials>QH</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yue-Mei</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Pei</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lin-Yang</ForeName><Initials>LY</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-Juan</ForeName><Initials>YJ</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yu-Ying</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yong-Chun</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Nian-Min</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Heng-Ming</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Sheng-Gen</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Ai</LastName><ForeName>Xing</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhen-Yu</ForeName><Initials>ZY</Initials></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Yu-Guo</ForeName><Initials>YG</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Feng-Ji</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao-Qin</ForeName><Initials>XQ</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ya</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Li-Wen</ForeName><Initials>LW</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zheng-Lun</ForeName><Initials>ZL</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Xin-Liang</ForeName><Initials>XL</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01508247</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000534">Alum Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>34S289N54E</RegistryNumber><NameOfSubstance UI="C041524">aluminum sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2013 Jun 8;381(9882):1968-70. doi: 10.1016/S0140-6736(13)61124-1</RefSource><PMID Version="1">23726163</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000534" MajorTopicYN="N">Alum Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007110" MajorTopicYN="N">Immunity, Active</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pii">S0140-6736(13)61049-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>